日本神经生物标记市场报告（按类型、应用、最终用途和地区）2025-2033

2024年，日本神经生物标记市场规模达5.914亿美元。展望未来， IMARC Group预计到2033年，该市场规模将达到9.553亿美元，2025-2033年期间的复合年增长率（CAGR）为5.50%。有效治疗方案的采用率不断上升，以及对快速药物开发的需求不断增长，是推动市场成长的主要动力。

神经生物标记存在于血液或脑脊髓液 (CSF) 中，有助于识别脑部疾病并追踪疾病进展。这些生物标记主要来自基因突变、代谢物水平、脑部影像以及蛋白质表现改变或翻译后修饰。神经生物标记物能够识别实验药物的生物反应，并有助于探索新的治疗介入靶点，因此在整个药物开发过程中的临床应用中发挥重要作用。目前，科学家透过分析这些生物标记的浓度，可以进行非侵入性检测、早期诊断和个人化治疗。

日本神经生物标记市场趋势：

日本神经系统生物标记市场正经历显着增长，这得益于神经系统疾病的日益流行，包括中风、运动神经元疾病 (MND)、阿兹海默症 (AD)、帕金森氏症 (PD) 和亨廷顿氏症 (HD)。神经系统疾病的激增催生了对加速药物开发的迫切需求，从而推动了市场的成长。此外，生物标记在衡量新型药物和治疗方法的有效性方面发挥关键作用，对这一发展势头做出了重要贡献。此外，微创手术和个人化医疗实践的日益普及，也成为该地区市场扩张的另一个重要催化剂。此外，由于各种神经系统疾病通常具有共同的特征，因此对多种生物标记的需求日益增长，以区分特定疾病及其亚型，这进一步刺激了市场需求。此外，质谱和成像技术的进步促进了对脑内多种生化标记和结构变化的快速评估，从而提高了诊断能力。再加上数位生物标记的引入和临床试验数量的持续增加，预计将在未来几年进一步推动日本神经生物标记市场的成长。

日本神经生物标记市场细分：

类型洞察：

• 基因组生物标记
• 蛋白质体生物标记
• 代谢组学生物标誌物
• 成像生物标记
• 其他的

应用程式洞察：

• 阿兹海默症
• 帕金森氏症
• 多发性硬化症
• 自闭症谱系障碍
• 其他的

最终用途洞察：

• 医院实验室
• 临床诊断中心
• 研究机构
• 其他的

竞争格局：

市场研究报告也对竞争格局进行了全面的分析。报告涵盖了市场结构、关键参与者定位、最佳制胜策略、竞争仪錶板和公司评估象限等竞争分析。此外，报告还提供了所有主要公司的详细资料。

本报告回答的关键问题：

• 日本神经生物标记市场迄今表现如何？未来几年将如何表现？
• COVID-19 对日本神经生物标记市场有何影响？
• 日本神经生物标记市场依类型分为哪些类型？
• 日本神经生物标记市场根据应用如何划分？
• 根据最终用途，日本神经生物标记市场是如何分類的？
• 日本神经生物标记市场的价值链分为哪些阶段？
• 日本神经生物标记的主要驱动因素和挑战是什么？
• 日本神经生物标记市场的结构是怎么样的？主要参与者是谁？
• 日本神经生物标记市场的竞争程度如何？

本报告回答的关键问题：

• 日本神经生物标记市场迄今表现如何？未来几年将如何表现？
• COVID-19 对日本神经生物标记市场有何影响？
• 日本神经生物标记市场依类型分为哪些类型？
• 日本神经生物标记市场根据应用如何划分？
• 根据最终用途，日本神经生物标记市场是如何分類的？
• 日本神经生物标记市场的价值链分为哪些阶段？
• 日本神经生物标记的主要驱动因素和挑战是什么？
• 日本神经生物标记市场的结构是怎么样的？主要参与者是谁？
• 日本神经生物标记市场的竞争程度如何？

目录

第一章：前言

第二章：范围与方法

• 研究目标
• 利害关係人
• 资料来源
  • 主要来源
  • 次要来源
• 市场评估
  • 自下而上的方法
  • 自上而下的方法
• 预测方法

第三章：执行摘要

第四章：日本神经生物标记市场 - 简介

• 概述
• 市场动态
• 产业趋势
• 竞争情报

第五章：日本神经生物标记市场格局

• 历史与当前市场趋势（2019-2024）
• 市场预测（2025-2033）

第六章：日本神经生物标记市场-分类：依类型

• 基因组生物标记
  • 概述
• 蛋白质体生物标记
  • 概述
• 代谢组学生物标誌物
  • 概述
• 成像生物标记
  • 概述
• 其他的

第七章：日本神经生物标记市场-细分：依应用

• 阿兹海默症
  • 概述
• 帕金森氏症
  • 概述
• 多发性硬化症
  • 概述
• 自闭症谱系障碍
  • 概述
• 其他的

第 8 章：日本神经生物标记市场 - 分裂：最终用途别

• 医院实验室
  • 概述
• 临床诊断中心
  • 概述
• 研究机构
  • 概述
• 其他的

第九章：日本神经生物标记市场-竞争格局

• 概述
• 市场结构
• 市场参与者定位
• 最佳获胜策略
• 竞争仪錶板
• 公司评估象限

第十章：关键参与者简介

• Company A
• Business Overview
• Services Offered
• Business Strategies
• SWOT Analysis
• Major News and Events
• Company B
• Business Overview
• Services Offered
• Business Strategies
• SWOT Analysis
• Major News and Events
• Company C
• Business Overview
• Services Offered
• Business Strategies
• SWOT Analysis
• Major News and Events
• Company D
• Business Overview
• Services Offered
• Business Strategies
• SWOT Analysis
• Major News and Events
• Company E
• Business Overview
• Services Offered
• Business Strategies
• SWOT Analysis
• Major News and Events

第 11 章：日本神经生物标记市场 - 产业分析

• 驱动因素、限制因素和机会
  • 概述
  • 驱动程式
  • 限制
  • 机会
• 波特五力分析
  • 概述
  • 买家的议价能力
  • 供应商的议价能力
  • 竞争程度
  • 新进入者的威胁
  • 替代品的威胁
• 价值链分析

第 12 章：附录

Japan neurological biomarkers market size reached USD 591.4 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 955.3 Million by 2033, exhibiting a growth rate (CAGR) of 5.50% during 2025-2033. The inflating adoption of effective treatment plans and the escalating demand for faster drug development are primarily driving the market growth.

Neurological biomarkers, found in either the blood or cerebral spinal fluid (CSF), serve to facilitate the identification of brain disorders and track the advancement of diseases. These biomarkers primarily originate from genetic mutations, levels of metabolites, brain imaging, and alterations in the expression of proteins or modifications after translation. With their ability to identify biological reactions to experimental medications and assist in the exploration of novel targets for therapeutic intervention, neurological biomarkers play a significant role in clinical applications throughout the drug development process. Currently, scientists analyze the concentrations of these biomarkers to enable non-invasive testing, early diagnosis, and the customization of treatments.

Japan Neurological Biomarkers Market Trends:

The Japan neurological biomarkers market is witnessing a notable upsurge owing to the escalating prevalence of neurological disorders, including conditions like stroke, motor neuron disease (MND), Alzheimer's disease (AD), Parkinson's disease (PD), and Huntington's disease (HD). This surge in neurological disorders has generated a pressing demand for accelerated drug development, thereby driving the market growth. Besides this, biomarkers play a pivotal role in measuring the effectiveness of novel medications and therapeutic approaches, contributing significantly to this momentum. Additionally, the growing acceptance of minimally invasive procedures and personalized medicine practices is serving as another crucial catalyst for market expansion in the region. Furthermore, as various neurological disorders often exhibit shared characteristics, there is an increasing requirement for multiple biomarkers to differentiate between specific diseases and their subtypes, further fueling market demand. Apart from this, advancements in mass spectrometry and imaging techniques have facilitated the rapid evaluation of numerous biochemical markers and structural changes within the brain, enabling enhanced diagnostic capabilities. This, coupled with the introduction of digital biomarkers and the continual rise in the number of clinical trials, is expected to further propel the growth of the Japan neurological biomarkers market in the forthcoming years.

Japan Neurological Biomarkers Market Segmentation:

Type Insights:

• Genomic Biomarkers
• Proteomic Biomarkers
• Metabolomic Biomarkers
• Imaging Biomarkers
• Others

Application Insights:

• Alzheimer's Disease
• Parkinson's Disease
• Multiple Sclerosis
• Autism Spectrum Disorders
• Others

End Use Insights:

• Hospital Laboratories
• Clinical Diagnostic Centers
• Research Organizations
• Others

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

Key Questions Answered in This Report:

• How has the Japan neurological biomarkers market performed so far and how will it perform in the coming years?
• What has been the impact of COVID-19 on the Japan neurological biomarkers market?
• What is the breakup of the Japan neurological biomarkers market on the basis of type?
• What is the breakup of the Japan neurological biomarkers market on the basis of application?
• What is the breakup of the Japan neurological biomarkers market on the basis of end use?
• What are the various stages in the value chain of the Japan neurological biomarkers market?
• What are the key driving factors and challenges in the Japan neurological biomarkers?
• What is the structure of the Japan neurological biomarkers market and who are the key players?
• What is the degree of competition in the Japan neurological biomarkers market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Japan Neurological Biomarkers Market - Introduction

• 4.1 Overview
• 4.2 Market Dynamics
• 4.3 Industry Trends
• 4.4 Competitive Intelligence

5 Japan Neurological Biomarkers Market Landscape

• 5.1 Historical and Current Market Trends (2019-2024)
• 5.2 Market Forecast (2025-2033)

6 Japan Neurological Biomarkers Market - Breakup by Type

• 6.1 Genomic Biomarkers
  • 6.1.1 Overview
  • 6.1.2 Historical and Current Market Trends (2019-2024)
  • 6.1.3 Market Forecast (2025-2033)
• 6.2 Proteomic Biomarkers
  • 6.2.1 Overview
  • 6.2.2 Historical and Current Market Trends (2019-2024)
  • 6.2.3 Market Forecast (2025-2033)
• 6.3 Metabolomic Biomarkers
  • 6.3.1 Overview
  • 6.3.2 Historical and Current Market Trends (2019-2024)
  • 6.3.3 Market Forecast (2025-2033)
• 6.4 Imaging Biomarkers
  • 6.4.1 Overview
  • 6.4.2 Historical and Current Market Trends (2019-2024)
  • 6.4.3 Market Forecast (2025-2033)
• 6.5 Others
  • 6.5.1 Historical and Current Market Trends (2019-2024)
  • 6.5.2 Market Forecast (2025-2033)

7 Japan Neurological Biomarkers Market - Breakup by Application

• 7.1 Alzheimer's Disease
  • 7.1.1 Overview
  • 7.1.2 Historical and Current Market Trends (2019-2024)
  • 7.1.3 Market Forecast (2025-2033)
• 7.2 Parkinson's Disease
  • 7.2.1 Overview
  • 7.2.2 Historical and Current Market Trends (2019-2024)
  • 7.2.3 Market Forecast (2025-2033)
• 7.3 Multiple Sclerosis
  • 7.3.1 Overview
  • 7.3.2 Historical and Current Market Trends (2019-2024)
  • 7.3.3 Market Forecast (2025-2033)
• 7.4 Autism Spectrum Disorders
  • 7.4.1 Overview
  • 7.4.2 Historical and Current Market Trends (2019-2024)
  • 7.4.3 Market Forecast (2025-2033)
• 7.5 Others
  • 7.5.1 Historical and Current Market Trends (2019-2024)
  • 7.5.2 Market Forecast (2025-2033)

8 Japan Neurological Biomarkers Market - Breakup by End Use

• 8.1 Hospital Laboratories
  • 8.1.1 Overview
  • 8.1.2 Historical and Current Market Trends (2019-2024)
  • 8.1.3 Market Forecast (2025-2033)
• 8.2 Clinical Diagnostic Centers
  • 8.2.1 Overview
  • 8.2.2 Historical and Current Market Trends (2019-2024)
  • 8.2.3 Market Forecast (2025-2033)
• 8.3 Research Organizations
  • 8.3.1 Overview
  • 8.3.2 Historical and Current Market Trends (2019-2024)
  • 8.3.3 Market Forecast (2025-2033)
• 8.4 Others
  • 8.4.1 Historical and Current Market Trends (2019-2024)
  • 8.4.2 Market Forecast (2025-2033)

9 Japan Neurological Biomarkers Market - Competitive Landscape

• 9.1 Overview
• 9.2 Market Structure
• 9.3 Market Player Positioning
• 9.4 Top Winning Strategies
• 9.5 Competitive Dashboard
• 9.6 Company Evaluation Quadrant

10 Profiles of Key Players

• 10.1 Company A
  • 10.1.1 Business Overview
  • 10.1.2 Services Offered
  • 10.1.3 Business Strategies
  • 10.1.4 SWOT Analysis
  • 10.1.5 Major News and Events
• 10.2 Company B
  • 10.2.1 Business Overview
  • 10.2.2 Services Offered
  • 10.2.3 Business Strategies
  • 10.2.4 SWOT Analysis
  • 10.2.5 Major News and Events
• 10.3 Company C
  • 10.3.1 Business Overview
  • 10.3.2 Services Offered
  • 10.3.3 Business Strategies
  • 10.3.4 SWOT Analysis
  • 10.3.5 Major News and Events
• 10.4 Company D
  • 10.4.1 Business Overview
  • 10.4.2 Services Offered
  • 10.4.3 Business Strategies
  • 10.4.4 SWOT Analysis
  • 10.4.5 Major News and Events
• 10.5 Company E
  • 10.5.1 Business Overview
  • 10.5.2 Services Offered
  • 10.5.3 Business Strategies
  • 10.5.4 SWOT Analysis
  • 10.5.5 Major News and Events

11 Japan Neurological Biomarkers Market - Industry Analysis

• 11.1 Drivers, Restraints, and Opportunities
  • 11.1.1 Overview
  • 11.1.2 Drivers
  • 11.1.3 Restraints
  • 11.1.4 Opportunities
• 11.2 Porters Five Forces Analysis
  • 11.2.1 Overview
  • 11.2.2 Bargaining Power of Buyers
  • 11.2.3 Bargaining Power of Suppliers
  • 11.2.4 Degree of Competition
  • 11.2.5 Threat of New Entrants
  • 11.2.6 Threat of Substitutes
• 11.3 Value Chain Analysis

12 Appendix